Skip to main content

Table 5 Shifts in LOCS III scores and IOP (Week 52; ophthalmological population)

From: Bone and ocular safety of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a 52-week randomized study

 

BGF MDI 320/18/9.6 μg (N = 132)

BFF MDI 320/9.6 μg (N = 54)

GFF MDI 18/9.6 μg (N = 125)

Proportion of patients with increases in LOCS III P score, n (%)

n

111

49

94

 Class 1 (≥0.5 unit)

16 (14.4)

6 (12.2)

7 (7.4)

 Class 2 (≥1.0 unit)

12 (10.8)

3 (6.1)

5 (5.3)

 Class 3 (≥1.5 units)

8 (7.2)

0

4 (4.3)

Proportion of patients with increases in LOCS III NO score, n (%)

n

111

49

95

 Class 1 (≥0.5 unit)

40 (36.0)

16 (32.7)

33 (34.7)

 Class 2 (≥1.0 unit)

19 (17.1)

5 (10.2)

11 (11.6)

 Class 3 (≥1.5 units)

6 (5.4)

2 (4.1)

3 (3.2)

Proportion of patients with increases in LOCS III NC score, n (%)

n

111

49

95

 Class 1 (≥0.5 unit)

30 (27.0)

12 (24.5)

32 (33.7)

 Class 2 (≥1.0 unit)

11 (9.9)

4 (8.2)

14 (14.7)

 Class 3 (≥1.5 units)

5 (4.5)

1 (2.0)

3 (3.2)

Proportion of patients with increases in LOCS III C score, n (%)

n

110

49

95

 Class 1 (≥0.5 unit)

25 (22.7)

10 (20.4)

17 (17.9)

 Class 2 (≥1.0 unit)

15 (13.6)

6 (12.2)

5 (5.3)

 Class 3 (≥1.5 units)

8 (7.3)

4 (8.2)

4 (4.2)

Proportion of patients with IOP ≥22 mmHg or increase in IOP of ≥7 mmHg, n (%)#

n

114

50

103

  ≥22 mmHg

2 (1.8)

3 (6.0)

4 (3.9)

  ≥7 mmHg increase

5 (4.4)

2 (4.0)

3 (2.9)

  1. BFF Budesonide/formoterol fumarate, BGF Budesonide/glycopyrrolate/formoterol fumarate, C Cortical cataract, GFF Glycopyrrolate/formoterol fumarate, IOP Intraocular pressure, LOCS III Lens opacities classification system III, MDI Metered dose inhaler, NC Nuclear color, NO Nuclear opalescence, P Posterior subcapsular cataract. #: in either eye